Abstract
About 10% to 20% of patients considered cured of COVID-19 may have changes in the body that lead them to develop COVID-19. Therapeutic alternatives for treatment have been applied in post-COVID-19 clinical management, phytotherapy stands out as an important clinical path. The objective of this study was to carry out a descriptive analysis on the use and application of herbal medicines in the portion of the population affected by COVID-long. This is a narrative review, with data collection in an exploratory way by expertise in the clinical and phytotherapy area. The qualitative approach was carried out from the perspective of identifying and applying the use of herbal medicines within the scope of Primary Health Care (PHC) for the treatment of symptoms in COVID-long. The findings signal an important investigative niche for short- to medium-term treatments in long-term COVID-19. Uncaria tomentosa for cough treatment, Ginkgo biloba for cardiovascular involvement; Mangifera indica Linneaus for neuromuscular and Valeriana officinalis for the Central Nervous System. Some studies may suggest the standardization of herbal medicines in the Unified Health System for their use in PHC as an adjuvant to treatment associated with allopathic medicines.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
